Tham khảo Tiền_chất

  1. 1 2 Rautio J, Meanwell NA, Di L, Hageman MJ (tháng 8 năm 2018). “The expanding role of prodrugs in contemporary drug design and development”. Nature Reviews. Drug Discovery (bằng tiếng Anh) 17 (8): 559–587. PMID 29700501. doi:10.1038/nrd.2018.46. 
  2. 1 2 3 Hacker M, Messer WS, Bachmann KA (19 tháng 6 năm 2009). “Chapter 10.5: Elimination (Metabolism and Excretion)”. Pharmacology: Principles and Practice. Academic Press. tr. 216–217. ISBN 978-0-08-091922-5. 
  3. ↑ Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC (2009). “The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine”. Current Medicinal Chemistry 16 (33): 4481–9. PMID 19835561. doi:10.2174/092986709789712835. 
  4. ↑ Stella VJ, Charman WN, Naringrekar VH (tháng 5 năm 1985). “Prodrugs. Do they have advantages in clinical practice?”. Drugs 29 (5): 455–73. PMID 3891303. doi:10.2165/00003495-198529050-00002. 
  5. ↑ Sneader W (2000). “The discovery of aspirin: a reappraisal”. BMJ 321 (7276): 1591–4. PMC 1119266. PMID 11124191. doi:10.1136/bmj.321.7276.1591. 
  6. ↑ Schrör K (2009). Acetylsalicylic acid. ISBN 978-3-527-32109-4. 
  7. ↑ UK Medicines Information Pharmacists Group. New Medicines on the Market: Desloratidine. Error in Webarchive template: Empty url. June 2001.
  8. 1 2 3 Wu KM (tháng 10 năm 2009). “A New Classification of Prodrugs: Regulatory Perspectives”. Pharmaceuticals 2 (3): 77–81. PMC 3978533. PMID 27713225. doi:10.3390/ph2030077. 
  9. ↑ Wu KM, Farrelly JG (tháng 7 năm 2007). “Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology”. Toxicology 236 (1–2): 1–6. PMID 17507137. doi:10.1016/j.tox.2007.04.005.